Success is never a straight line—reflecting on our EMA draft qualification opinion
March 31, 2022
On March 22, 2022, we reached an historic milestone with the European Medicines Agency’s release of a draft qualification opinion on our 3-step PROCOVA™ procedure.
To solve the problem of trial inefficiency, clinical trial sponsors are turning to external data sources to supplement and increase efficiency of clinical trials.
Propensity Score Matching: A Method of Last Resort?
October 29, 2019
While propensity score matching makes it easier to match subjects with complex covariates, it generates a less precise estimate of how effective a drug is.
How Many People Do We Need to Find an Exact Match?
October 14, 2019
The goal of this post is to show (by way of a lottery analogy) that if we want to find an exact match for a subject with Alzheimer's, we would need a dataset with millions of patients -- an infeasible
Reflections on AAIC 2019: Community, Cause, and Challenges
July 29, 2019
While treating the patient is the utmost priority, we need to understand that Alzheimer’s impacts every part of a person’s life and to address all of those parts, both effectively and compassionately.
Better Clinical Trials without Statistical Significance
July 16, 2019
To take into account uncertainty, we should be conservative and estimate the smallest treatment effect that we would expect to observe over many repeated studies.
The Advantages of Modeling Clinical Data for Control Arms
October 10, 2018
Models are the key to unlocking the full potential of historical data to inform current trials with a broad spectrum of trial designs and patient covariates.
Imagine a computational biologist who wants to build a model to predict the prognosis of a patient with Alzheimer’s disease. What variables should he choose?